このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal Liver Metastases

Clinical Utility Evaluation of a Surgical Sequencing Decision-Support Software in Simulated Cases of Colorectal Liver Metastases: A Multicenter Prospective Study (COLORS-Validate Study)

This study evaluates a surgical decision-support software designed to assist physicians in selecting the optimal surgical sequence for patients with colorectal cancer liver metastases.

In this multicenter prospective simulation study, participating surgeons from multiple centers will review standardized clinical case scenarios. For each case, physicians will first make a surgical sequencing decision based on their own clinical judgment. They will then review the recommendation provided by the decision-support software and make a second decision if they choose to revise their initial plan.

The study will assess whether the software influences clinical decision-making, including changes in surgical strategy, decision confidence, decision time, and agreement with software recommendations. Physician user experience will also be evaluated using standardized questionnaires, including system usability and cognitive workload scales.

The goal of this study is to determine the clinical utility and usability of the decision-support software in improving surgical decision-making consistency and supporting clinical reasoning in colorectal liver metastases cases.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

The selection of surgical sequencing-whether to resect the primary tumor first or the liver metastases first-in patients with colorectal cancer liver metastases (CRLM) undergoing synchronous resection represents a critical and highly complex decision in current clinical practice. With the advancement of systemic therapies and surgical techniques, an increasing number of patients with initially unresectable CRLM have gained the opportunity for surgical treatment. However, due to substantial heterogeneity among patients in terms of tumor burden, biological behavior of the disease, and overall physical condition, no unified standard currently exists for determining the optimal surgical sequence. Existing studies comparing different surgical strategies have yielded inconsistent prognostic results, and most are based on retrospective analyses lacking consistent conclusions and clear stratification criteria. Consequently, in real-world clinical practice, such decisions rely heavily on physician experience and institutional preference, resulting in considerable inter-physician variability and uncertainty. This scenario, characterized by the absence of a clearly optimal strategy, renders the decision-making process inherently a form of decision-making under uncertainty.

Based on this context, we previously developed, using multicenter retrospective data, two multi-outcome predictive models corresponding to different surgical strategies. These models integrate postoperative major complications, Comprehensive Complication Index (CCI), progression-free survival (PFS), and overall survival (OS), and have been externally validated. However, in real-world clinical decision-making, the central challenge faced by surgeons is not merely the prediction of a single outcome, but rather the need to balance multiple competing outcomes. For example, one surgical strategy may be associated with a lower risk of postoperative complications but limited long-term survival benefit, whereas another may involve higher perioperative risk in exchange for improved oncological outcomes. This inherent tension among multidimensional outcomes transforms clinical decision-making into a multi-objective decision-making problem, rather than a simple comparison of a single endpoint.

In current practice, such trade-offs across outcomes are typically based on physicians' experiential judgment, whereby the relative importance of different outcomes is implicitly weighted. However, this weighting process lacks explicit representation and standardized criteria, and is prone to influence by individual experience, risk preference, and institutional norms, thereby leading to substantial variability and inconsistency in decision-making. To address this key limitation, the present study further constructs a structured multi-outcome weighting framework using the Delphi method combined with the analytic hierarchy process (AHP). This approach establishes the relative importance of different clinical outcomes through expert consensus and translates it into a quantifiable weighting system, thereby enabling the integration of multidimensional predictive results into a comparable composite score. Based on this framework, we developed a decision-support software system capable of simultaneously providing individualized multi-outcome predictions and composite reference scores, transforming the previously experience-dependent implicit trade-off process into a transparent, interpretable, and standardized decision-support process.

Nevertheless, the establishment of predictive models and weighting frameworks does not necessarily translate into practical clinical value. For decision-support systems, focusing solely on predictive performance is insufficient to reflect their real-world clinical utility. More importantly, it is necessary to evaluate whether such systems can influence physician decision-making behavior under uncertainty, reduce unnecessary variability, and provide a structured reference framework for decision-making. In addition, because clinical decision-making involves counterfactual comparisons (i.e., potential outcomes under alternative strategies for the same patient cannot be simultaneously observed), traditional outcome-based evaluation methods have inherent limitations. Therefore, it is necessary to adopt a model-informed standardized reference framework to evaluate the impact of AI assistance at the level of decision behavior.

Based on the above considerations, this study adopts a multicenter, prospective crossover simulation design to systematically evaluate the clinical utility of the decision-support system in a standardized setting. The evaluation focuses on the following two dimensions:

  1. From a scientific decision perspective: whether the system alters physician decision behavior, improves decision consistency, and reduces variability;
  2. From a human factors perspective: whether the system affects cognitive load, decision confidence, and user experience.

This study extends AI evaluation beyond predictive performance toward its influence on decision-making behavior, with a particular focus on the human-AI collaborative decision-making process in uncertain clinical scenarios.

研究の種類

観察的

入学 (推定)

12

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

This study will enroll physicians from three tertiary academic medical centers in China, including hepatobiliary surgeons and colorectal surgeons with varying levels of clinical experience. Participants will be required to complete standardized simulation-based case evaluations involving surgical decision-making for colorectal cancer liver metastases. The study aims to assess changes in decision-making behavior, confidence, and usability of a decision-support software system.

説明

Inclusion Criteria:

  • Licensed physicians specializing in hepatobiliary surgery or colorectal surgery
  • At least 1 year of clinical experience after graduation
  • Willing to participate in the simulation-based decision-making study
  • Practicing at one of the participating tertiary academic hospitals

Exclusion Criteria:

  • Not actively involved in clinical surgical decision-making
  • Unable to complete all required simulation sessions
  • Prior involvement in the development of the decision-support software

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Unaided Clinical Decision-Making
Physicians make surgical sequencing decisions based on routine clinical judgment without decision-support software.
Usual Clinical Decision-Making (Without Decision Support Software)
Decision-Support Software-Assisted Decision-Making
Physicians make surgical sequencing decisions after reviewing recommendations from the decision-support software.
Physicians make surgical sequencing decisions after reviewing recommendations generated by the decision-support software, including weighted scores and predicted outcomes.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Surgical Decision-Making Between Software-Assisted and Non-Assisted Conditions
時間枠:During each simulated case evaluation session
The primary outcome is the proportion of cases in which physicians change their surgical sequencing decision after reviewing decision-support software recommendations compared with their initial unaided decision.
During each simulated case evaluation session

二次結果の測定

結果測定
メジャーの説明
時間枠
Software utilization outcomes
時間枠:During each simulated case evaluation session
Software adoption rate (agreement between final decision and software recommendation); Post-change adoption rate among changed decisions
During each simulated case evaluation session
Decision performance outcomes
時間枠:During each simulated case evaluation session
Decision-making time (seconds per case); Inter-group comparison between unaided and software-assisted conditions
During each simulated case evaluation session
Human factors outcomes
時間枠:During each simulated case evaluation session
Decision confidence score (5-point Likert scale)
During each simulated case evaluation session

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Hong Zhao, MD、Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月1日

一次修了 (推定)

2026年9月30日

研究の完了 (推定)

2026年10月30日

試験登録日

最初に提出

2026年7月23日

QC基準を満たした最初の提出物

2026年8月10日

最初の投稿 (実際)

2026年8月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月12日

QC基準を満たした最後の更新が送信されました

2026年8月10日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCC-023039

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly shared because of participant confidentiality, institutional data-protection requirements, and the potential risk of re-identification given the characteristics and size of the study population. Aggregate study results will be reported in peer-reviewed publications.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。